Sai Parenteral's Limited

[-]

Offer Period :

-

Sai Parenteral's Limited IPO Details

IPO Date - - - Minimum Investment ₹ / Lots
Listing Date - Maximum Investment ₹ / Lots
Face Value ₹0 per share Total Issue Size ₹0 Crores
Price ₹0 to ₹0 per share Fresh Issue ₹0 Crores
Lot Size 1 Lots (0 Shares) Offer For Sale ₹ NA
Listing At Retail Discount ₹ 0
Employee Discount ₹0 per Share Shareholding Pre Issue 3,69,08,823 Shares
Issue Type Shareholding Post Issue 0 Shares
IPO Date - - -
Listing Date -
Face Value ₹0 per share
Price ₹0 to ₹0 per share
Lot Size 1 Lots (0 Shares)
Listing At
Total Issue Size ₹0 Crores
Employee Discount ₹0 per share
Issue Type
Minimum Investment ₹ / Lots
Maximum Investment ₹ / Lots
Fresh Issue ₹0 Crores
Offer For Sale ₹NA Crores
Retail Discount ₹0 Crores
Shareholding Pre Issue 3,69,08,823 Shares
Shareholding Post Issue 0 Shares

About Sai Parenteral's Limited IPO

Founding Head:

Managing Director: [-]

Sai Parenteral's Limited Timeline

Important dates for allocation and IPO listing.

-

IPO Opens

-

IPO Close

-

Allotment Date

-

Initiation of Refund

-

Credit of Shares to Demat Account

-

IPO Listing Date

Shareholder Pattern

  Pre-Issue Post-Issue
Promoter Group 0 0
Public Group 100 100

Sai Parenteral's Limited IPO Reservation

QIB Shares Offered 0(0%)
NII (HNI) Shares Offered 0(0%)
Retail Shares Offered 0(0%)
Anchor Investor Shares Offered 0(0%)
Total Shares Offered 0
Total Shares With Anchor Investor 0

Sai Parenteral's Limited IPO Lot Size

Application Lots Shares Amount
Retail (Min) [-] [-] ₹[-]
Retail (Max) [-] [-] ₹[-]
S HNI (Min) [-] [-] ₹[-]
S HNI (Max) [-] [-] ₹[-]
B HNI (MIN) [-] [-] ₹[-]

Sai Parenteral's Limited IPO Anchor Investor Details

Bid Date
Shares Offered
Anchor Portion Size

Sai Parenteral's Limited IPO Registrar

Bigshare Services Pvt Ltd
Phone Number +91 22 6263 8200
Email Id ipo@bigshareonline.com
Our Website www.bigshareonline.com

Sai Parenteral's Limited IPO Lead Manager

1. Arihant Capital Markets Limited

Explore IPOs


Explore comprehensive IPO details for every IPO. Access essential information such as listing price, listing date, issue price, lot size, issue size, minimum investment, and IPO timeline. Gain insights into the company's background, strengths, and potential risks. Track the subscription status and delve into the financials of the company, empowering yourself with crucial data for informed investment decisions. Stay ahead in the dynamic IPO market by staying informed on upcoming, ongoing, and past IPOs. 
 

Stay ahead in the ever-evolving IPO landscape with our comprehensive platform. We offer a holistic resource, ensuring you not only access essential details but also gain valuable insights into market trends. Navigate confidently, armed with intricate analyses, expert opinions, and real-time updates. Whether you're a seasoned investor or a novice, our user-friendly interface and extensive information empower you to make well-informed decisions. Experience the convenience of having a dedicated space where you can delve into the intricacies of IPOs, enabling a strategic and calculated approach to the dynamic stock market. 

Sai Parenteral's Limited Financial Information

Period Ended March 31, 2025 March 31, 2024 March 31, 2023
Net Worth ₹93.67 ₹74.54 ₹31.49
Reserves and Surplus ₹80.36 ₹61.3 ₹24.33
Total Borrowing ₹93.95 ₹118.79 ₹68.55

Sai Parenteral's Limited IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid No. of subscribed
Qualified Institutional Buyers (QIBs) 0 0 0
Non Institutional Investors (NIIs) 0 0 0
NII(Bid amount of more than Ten Lakh Rupees) 0 0 0
NII(Bid amount of more than 2 Lakh < 10 Rupees) 0 0 0
Retail Individual Investors (RIIs) 0 0 0
Total 0 0 0

Strength of Sai Parenteral's Limited

1. Diversified generic formulations player with an established track record.

2. Strategically located and accredited Manufacturing Facilities.

3. Strong focus on CDMO business.

4. Well-established sales network in India and overseas.

5. Track record of value-accretive acquisitions.

6. Experienced Promoters and Senior Management with extensive domain knowledge.

Risks Involved

1. The company's Manufacturing Facilities are concentrated in Hyderabad, Telangana and Ongole, Andhra Pradesh. The company is exposed to risks originating from slowdown or shutdown, economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.

2. Out of its diversified product portfolio, approximately 44.78%, 47.64% and 92.03% during the Fiscals 2025, 2024 and 2023, respectively of the company's Net Revenue from Operations was derived from the sale of injectables. Any reduction in demand for these products may adversely affect its business, financial condition, results of operations and cash flows.

3. The company's Manufacturing Facilities are subject to periodic inspections and audits by regulatory authorities and customers. The company may be subject to regulatory action which may damage its reputation, leading to an adverse effect on the company's business, results of operations, financial condition and cash flows.

4. Majority of its key raw material purchases, being APIs, excipients and intermediates, are sourced from a diversified supplier base, and the company does not enter into is not any long-term contractual agreements with them. Any reduction of supplies or discontinuation of supplies from its top suppliers could have a material adverse effect on the company's business, financial condition, results of operations and cash flows. Any fluctuation in prices of its raw materials may have a material adverse effect on the company's business, results of operations, prospects and financial condition.

5. The company's success depends on its ability to successfully develop and commercialize new products in a timely manner. Any failures to do so could adversely affect the company's business, results of operations and financial condition.

6. The company's business is dependent on the sale of products to a limited number of customers for a significant portion of its revenues. The loss of one or more such customers or the deterioration of their financial condition or prospects could adversely affect its business, results of operations and financial condition.

7. The company's international business exposes us to complex management, legal, tax and economic risks, which could adversely affect its business, results of operations and financial condition.

8. There are outstanding legal proceedings involving the Company, Promoters, some of its Directors and, the company's Material Subsidiary.

9. The company plans to expand and/or upgrade its Manufacturing Facilities from the Net Proceeds of the Fresh Issue and will be required to briefly stop operations in Unit I and II till such plans are completed. The company has estimated a period of 6 months for this disruption before both these units can resume operations. The company is also dependent on third-party contractors and specialist agencies who will be executing the proposed expansion and/or upgradation plans.

10. The Indian pharmaceutical market is subject to extensive regulation and its failures to comply with the existing and future regulatory requirements in the pharmaceutical market could adversely affect the company's business, results of operations and financial condition.

Why should you invest in

-

Sai Parenteral's Limited Financials

Particulars For the financial year ending (in ₹ million)
  2025 2024 2023
Total Assets 272.39 268.1 133.96
Total Liabilities 272.39 268.1 133.96
Total Expenses 143.84 142.62 89.78
Total Revenue 
163.74 155.18 97.03
Profit After Tax 14.45 8.41 4.38
EBITDA 40.02 33.08 17.86
Adjusted EBITDA 0 0 0

Sai Parenteral's Limited IPO Contact Details

Sai Parenteral's Limited IPO Listing Details

Listing Date BSE Script Code NSE Symbol ISIN Final Issue Price
0 -
INE0H9F01037
₹0 per share

Listing Day Trading Information

Price Details BSE NSE
Final Issue Price ₹0 ₹0
Open ₹0 ₹0
Low ₹0 ₹0
High ₹0 ₹0
Low ₹0 ₹0

Frequently Asked Questions

What is Sai Parenteral's Limited IPO?

Answer Field

Sai Parenteral's Limited IPO is a IPO of [-] equity shares of a face value of ₹[-] aggregating up to ₹[-] Crores. The issue is priced at ₹[-] to ₹[-] per share. The minimum order quantity is [-] Shares. The IPO opens on [-], and closes on [-]. Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on .

When Sai Parenteral's Limited IPO will open?

Answer Field

The Sai Parenteral's Limited IPO opens on [-] and closes on [-].

What is the lot size of Sai Parenteral's Limited?

Answer Field

Sai Parenteral's Limited lot size is [-] shares, and the minimum amount required is ₹[-].

How to apply for Sai Parenteral's Limited IPO?

Answer Field

You can apply in Sai Parenteral's Limited IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Sai Parenteral's Limited IPO allotment?

Answer Field

The finalization of Basis of Allotment for Sai Parenteral's Limited IPO will be done on [-], and the allotted shares will be credited to your demat account by [-].

When is Sai Parenteral's Limited IPO listing date?

Answer Field

The Sai Parenteral's Limited listing date is [-].

Who is the registrar of Sai Parenteral's Limited IPO?

Answer Field

The registrar of Sai Parenteral's Limited IPO is Bigshare Services Pvt Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

Arihant Capital Markets Limited will be the book-running lead manager of this IPO.

What is the fresh issue of Sai Parenteral's Limited IPO?

Answer Field

The fresh issue size is ₹[-] Crores equity shares.

What minimum lot size can retail subscribers subscribe to Sai Parenteral's Limited?

Answer Field

Retail investors can subscribe to a minimum of one lot, [-] shares and ₹[-] amount.

How can I approve the UPI mandate request for Sai Parenteral's Limited IPO?

Answer Field

To apply for Sai Parenteral's Limited IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Sai Parenteral's Limited?

Answer Field

The price of each Sai Parenteral's Limited share will be ranging in between ₹[-] to ₹[-] per share.

What is the cut-off time for the UPI mandate for Sai Parenteral's Limited IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, [-].

No results found

Browse IPOs

upcoming-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
current-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
closed-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
performance-radio
  • IPO Name
  • ISSUE PRICE
  • LISTING DAY CLOSE
  • LISTING DAY(GAIN/LOSS)

We have something for everyone

Explore more Investment options

Mutual Funds

Choose from 4000+ mutual funds and invest seamlessly 

investment-card-icon

IPOs

Your gateway to invest early in tomorrow's market leaders

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

Bonds

Diversify your investment portfolio with bonds

investment-card-icon

Related Articles

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.8 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,300+ Cr MTF Book

icon-with-text